Ludovic Helfgott/LinkedIn
Nov 15, 2025, 15:45
Ludovic Helfgott: Researchers Have Analysed Novo Nordisk Product Data in Obesity and Cardiovascular Disease
Ludovic Helfgott, Executive Vice President, Product and Portfolio Strategy at Novo Nordisk, shared a post on LinkedIn:
“New paper in The Lancet Group today. Researchers have analysed Novo Nordisk product data in obesity and cardiovascular disease and the results suggest that a reduction of major adverse cardiovascular events in people with overweight or obesity is independent of baseline weight and weight loss.
These findings again support our strategy to reduce the risk of cardiovascular events for the hundreds of millions of people living with overweight or obesity and cardiovascular disease and promote their long-term health.”
Stay updated with Hemostasis Today.
-
Mar 12, 2026, 12:05Kent H: The Lymphatic System – The Unsung Hero of Detox
-
Mar 12, 2026, 11:55Akinchan Bhardwaj: Exercise Biological Modifier of Vascular Trajectory
-
Mar 12, 2026, 11:50Guy Young: Clinical Conversations on Gene Therapy Progress in Hemophilia B at THSNA 2026
-
Mar 12, 2026, 11:44Yves Bikorimana: Causes, Diagnosis, and Management of Neonatal Alloimmune Thrombocytopenia
-
Mar 12, 2026, 11:33Kymentie Ferdinande: New Insights Into Platelet Function and Thrombus Formation in Cirrhosis
-
Mar 12, 2026, 11:17Tareq Abadl: Why Do Some People Bruise And Bleed So Easily?
-
Mar 12, 2026, 11:15Matthew Flick: The Interplay of the Fibrinogen αC-Region, Hypofibrinogenemia, and GPVI in Arterial Thrombosis
-
Mar 12, 2026, 11:08Stephen Twumasi: The Impact of Hepatitis B Infection on the Coagulation System During Pregnancy
-
Mar 12, 2026, 11:05Robert Lufkin: One Minute of Wisdom from Robert Lustig on Cholesterol, Sugar, and Heart Disease